Atmospheric impacts of a natural gas development within the urban context of Morgantown, West Virginia.

The Marcellus Shale Energy and Environment Laboratory (MSEEL) in West Virginia provides a unique opportunity in the field of unconventional energy research. By studying near-surface atmospheric chemistry over several phases of a hydraulic fracturing event, the project will help evaluate the impact of current practices, as well as new techniques and mitigation technologies. A total of 10 mobile surveys covering a distance of approximately 1500 km were conducted through Morgantown. Our surveying technique involved using a vehicle-mounted Los Gatos Research gas analyzer to provide geo-located measurements of methane (CH4) and carbon dioxide (CO2). The ratios of super-ambient concentrations of CO2 and CH4 were used to separate well-pad emissions from the natural background concentrations over the various stages of well-pad development, as well as for comparisons to other urban sources of CH4. We found that regional background methane concentrations were elevated in all surveys, with a mean concentration of 2.699 ± 0.006 ppmv, which simply reflected the complexity of this riverine urban location. Emissions at the site were the greatest during the flow-back phase, with an estimated CH4 volume output of 20.62 ± 7.07 g/s, which was significantly higher than other identified urban emitters. Our study was able to successfully identify and quantify MSEEL emissions within this complex urban environment.

Inositol phosphoglycan P-type in infants of preeclamptic mothers.

BACKGROUND: Inositol phosphoglycan P-type (P-IPG) has consistently found to be elevated during active preeclampsia, although the biosynthetic source has to be identified yet. This multicenter prospective cross-sectional case-control study evaluated the fetus/newborn as the source of P-IPG. METHODS: A urine specimen was collected longitudinally for three consecutive days after delivery from 90 newborns and their mothers, and ordered according to clinical diagnosis of preeclampsia, gestational hypertension, or healthy pregnancy. RESULTS: The urinary excretion of P-IPG on day 0 was higher in the mothers in all groups (p < 0.05) with higher levels in preeclamptic women (p < 0.01) in the mothers compared to their newborns in the preeclamptic group (p<0.01). The difference persisted at least two days post partum. CONCLUSION: Findings of this study confirm the specificity of the increase in urinary excretion of P-IPG in preeclamptic mothers at day of birth compared to healthy pregnancy and GH, but does not extend to their newborns.

Inositol phosphoglycans and preeclampsia: from bench to bedside.

The metabolic syndrome that occurs in preeclampsia reflects the complex interactions between immunological alterations and the systemic inflammation that have been shown to take place during this complication of human pregnancy. Inositol phosphoglycans play a definite role in the insulin resistance in preeclampsia with a higher production and urinary excretion of this molecule before and during preeclampsia. Recent researches suggest that the feto-placental glucose metabolism in the first and early second trimester is mainly linked to the nonoxidative pathway of glycogen catabolism supporting the pivotal role of the inositol phosphoglycan P-type. In this article we present the results of a case-control study carried out in the first trimester to evaluate the potential of urinary P-IPG release as a early marker of the disease. A single mid-stream sample of maternal urine was collected at 11 weeks of gestation for this single centre retrospective study. Twenty-seven patients out of 331 women recruited (8.1%) went on to develop preeclampsia but no sample attained positivity. Further details about the development of the metabolic syndrome during preeclampsia were retrieved also from other studies to implement our knowledge about the pathophysiology of this syndrome and to identify biochemical aspects that could help in clinical practice.

Urinary inositol phosphoglycan P-type as a marker for prediction of preeclampsia and novel implications for the pathophysiology of this disorder.

OBJECTIVE: Hypertensive disorders represent the most common complications of human pregnancy with substantial impact on fetal and maternal outcomes. Inositol phosphoglycan P-type has recently been identified as a novel marker of preeclampsia, the most severe form of hypertension during pregnancy, with a significant increase in urinary excretion preceding the clinical diagnosis. METHODS: A prospective, longitudinal study was carried out to assess the potential of urinary levels of inositol phosphoglycan P-type as a screening test for preeclampsia. A specific ELISA-based test was used to assess urinary levels of P-IPG. RESULTS: Nine patients out of 93 women recruited (496 urinary samples were collected) went on to develop preeclampsia in a cohort of women with high-risk pregnancies. A cut-off value of urinary inositol phosphoglycan P-type was identified by ROC analysis providing a sensitivity and specificity for the current protocol of 88.9% and 62.7%, respectively. Twenty-three women with healthy pregnancies had sporadic episodes of increased excretion of inositol phosphoglycan P-type during pregnancy that consistently resolved back to normal baseline without development of preeclampsia. There was no correlation of urine levels of inositol phosphoglycan P-type and urine protein and patients with gestational hypertension had normal levels of urine inositol phosphoglycan P-type. CONCLUSIONS: These findings suggest that, given the rapid raise of P-IPG before the onset of the disease, multiple assessments may help at identifying women at risk of developing preeclampsia.

Inositol phosphoglycan P-type in preeclampsia: a novel marker?

A state of insulin resistance has been demonstrated in active preeclampsia, and women with clinical evidence of insulin resistance are at higher risk to develop this syndrome during pregnancy. Recently, inositol phosphoglycan P-type, a putative second messenger of insulin action, has been implicated in the pathophysiology of preeclampsia and is increased in the placenta, amniotic fluid, and maternal urine of preeclamptic women compared with normal pregnant women. We report here a case-control study to assess the potential of urinary levels of inositol phosphoglycan P-type as a screening test for preeclampsia. Twenty-seven preeclamptic women and 47 healthy pregnant women were recruited. A polyclonal antibody-based ELISA was developed to detect levels of inositol phosphoglycan P-type in urine. Its content in urinary specimens was found to be 30-fold higher in preeclamptic subjects than control subjects (329.1+/-21.8 versus 9.2+/-1.5; P<0.001), with a higher level in all of the preeclamptic cases. For 6 women who developed preeclampsia, >1 gestational date sample of urine was available, and retrospective analysis showed a significant time-related increase of the urinary level of inositol phosphoglycan P-type